Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine

Journal of Infectious Diseases

Volumn 192, Issue 7, 2005, Pages 1260-1264

  Lee, Esther J ^a   Kantor, Rami ^a   Zijenah, Lynn ^e   Sheldon, Wayne ^b   Emel, Lynda ^b   Mateta, Patrick ^e   Johnston, Elizabeth ^a   Wells, Jennifer ^e   Shetty, Avinash K ^e   Coovadia, Hoosen ^f   Maldonado, Yvonne ^a   Jones, Samuel Adeniyi ^c   Mofenson, Lynne M ^d   Contag, Christopher H ^a   Bassett, Mary ^e   Katzenstein, David A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SODIUM ION; VIRUS RNA;

ARTICLE; BREAST MILK; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EXPOSURE; FEMALE; GENE MUTATION; GENETIC SELECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASTITIS; NUCLEOTIDE SEQUENCE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION; ZIMBABWE;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MILK, HUMAN; NEVIRAPINE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS SHEDDING; ZIMBABWE;

EID: 25444510145     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/444424     Document Type: Article

References (15)

1. UNAIDS. UNAIDS questions and answers. Geneva: UNAIDS-World Health Organization, 2004.
2. Datta P, Embree JE, Kreiss JK, et al. Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi Study. J Infect Dis 1994; 170:1134-40.
3. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93-8.
4. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-68.
5. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-40.
6. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-5.
7. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7.
8. Shetty AK, Coovadia HM, Mirochnick MM, et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003; 34:482-90.
9. Los Alamos HIV Databases, 2004. Available at: http://hiv-web.lanl.gov.
10. Van de Peer Y, De Wachter R. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994; 10:569-70.
11. Gonzales MJ, Dugan JM, Shafer RW Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN). Bioinformatics 2002; 18:886-7.
12. Eshelman SH, Hoover D, Chen S, et al. Comparison of nevirapine resistance in women with subtype C compared with subtype A and after single-dose NVP [abstract 799]. In: Program and abstracts of the 12th Conference on Retrovirus and Opportunistic Infections (Boston). 2005.
13. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single dose nevirapine in a PMTCT cohort [abstract 38]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
14. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-86.
15. Becquart P, Chomont N, Roques P, et al. Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology 2002; 300:109-17.